BioTime Receives Second Round of Funding
The embryonic stem cell company BioTime receives $4 million in its second equity tranche.
July 13, 2009
The embryonic stem cell company BioTime receives $4 million in its second equity tranche.
There were approximately 49,000 comments sent into the NIH in response to a publicly available draft of the new guidelines to embryonic stem cell research.
New advances in instrumentation and laboratory technology are featured at this year’s ISSCR conference in Barcelona.
BioTime’s subsidiary, Embryome Sciences, enters into a co-marketing agreement with Millipore.
Merger of IZumi Bio and Pierian Inc was announced, with the new company being named IPierian.
Kenneth Kelley, an eight-year old child from the Bangor area will be the first person from Maine to receive adult stem cell therapy for autism.